Uncertainty About the Benefits of New Cancer Drugs and Patients' Treatment Preferences
Conditions
Interventions
- OTHER: Control
- OTHER: Unvalidates surrogate endpoint
- OTHER: Limited study population
- OTHER: Small magnitude of effect
- OTHER: Multiple uncertainties
Sponsor
London School of Economics and Political Science
Collaborators